✦ LIBER ✦

Bcr-Abl inhibition as a modality of CML therapeutics

✍ Scribed by Elisabeth Buchdunger; Alex Matter; Brian J. Druker

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Inhibition of the Bcr-Abl tyrosine kinas

✍ Druker, Brian J 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 134 KB

Bcr-abl kinase inhibition as the basis o

✍ Brian J. Druker; Moshe Talpaz; Debra Resta; Bin Peng; Eliasbeth Buchdunger; John 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 14 KB

Identification of E6A2 BCR-ABL fusion in

✍ Dupont, M; Jourdan, E; Chiesa, J 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB

Blocking cytokine signaling along with i

✍ Hiwase, D K; White, D L; Powell, J A; Saunders, V A; Zrim, S A; Frede, A K; Guth 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 613 KB

An accelerrated-phase CML patient with e

✍ Polák, J; Koza, V; Cetkovský, P; Haškovec, C 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 57 KB

Inhibition of Bcr–Abl kinase activity by

✍ Huang, Mei; Dorsey, Jay F; Epling-Burnette, P K; Nimmanapalli, Ramadevi; Landows 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 449 KB